Menu
← Oncology Approval Tracker
FDA DECISION ·
Trodelvy
sacituzumab govitecan-hziy · Gilead Sciences
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line monotherapy for adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1 or PD-L1 inhibitor-based therapy.
LAMPGEN ANALYSIS
Why it matters
ASCENT-03 brings a TROP2-directed antibody-drug conjugate into the first-line setting for patients who cannot receive checkpoint inhibitor-based therapy.
What research teams should watch
Document why the patient is ineligible for checkpoint therapy, then track baseline status, neutropenia and diarrhea. Keep this population separate from the PD-L1-selected combination.
PRIMARY RECORDS